Atossa Therapeutics Stock Cash And Equivalents
| YAG2 Stock | EUR 1.20 0.01 0.83% |
Atossa Therapeutics fundamentals help investors to digest information that contributes to Atossa Therapeutics' financial success or failures. It also enables traders to predict the movement of Atossa Stock. The fundamental analysis module provides a way to measure Atossa Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Atossa Therapeutics stock.
Atossa |
Atossa Therapeutics Company Cash And Equivalents Analysis
Atossa Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Atossa Therapeutics Cash And Equivalents | 131.49 M |
Most of Atossa Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Atossa Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Atossa Therapeutics has 131.49 M in Cash And Equivalents. This is 83.98% lower than that of the Healthcare sector and 70.59% lower than that of the Biotechnology industry. The cash and equivalents for all Germany stocks is 95.13% higher than that of the company.
Atossa Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atossa Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atossa Therapeutics could also be used in its relative valuation, which is a method of valuing Atossa Therapeutics by comparing valuation metrics of similar companies.Atossa Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Atossa Fundamentals
| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 | |||
| Current Valuation | (59.13 M) | |||
| Shares Outstanding | 126.62 M | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 20.65 % | |||
| Price To Book | 0.64 X | |||
| EBITDA | (20.5 M) | |||
| Net Income | (20.61 M) | |||
| Cash And Equivalents | 131.49 M | |||
| Cash Per Share | 1.04 X | |||
| Total Debt | 1.22 K | |||
| Current Ratio | 58.94 X | |||
| Book Value Per Share | 0.97 X | |||
| Cash Flow From Operations | (16.47 M) | |||
| Earnings Per Share | (0.17) X | |||
| Target Price | 7.75 | |||
| Beta | 1.27 | |||
| Market Capitalization | 88.42 M | |||
| Total Asset | 141.26 M | |||
| Net Asset | 141.26 M |
About Atossa Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atossa Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atossa Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atossa Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Atossa Stock
Atossa Therapeutics financial ratios help investors to determine whether Atossa Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Atossa with respect to the benefits of owning Atossa Therapeutics security.